Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Unknown 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 7Breast 5Other hematologic neoplasm 4Lymphoid 4Plasma cell 3Thoracic 2Head & Neck 2Tumor-Agnostic 1Sarcoma 1Other 1Myeloid 1Gynecologic 1

Conditions

Recurrence 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1

Interventions

Rituximab 1401Cyclophosphamide 1305Vincristine 668Doxorubicin 587Etoposide 527Prednisone 510Cytarabine 486fludarabine 469Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 260ibrutinib 258obinutuzumab 235Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Clinical Protocols × Lymphoid × Clear all
NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
50 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT05772728 2023-03-16

Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)

The First Affiliated Hospital with Nanjing Medical University

Phase NA Unknown
23 enrolled
Lymphoid

Lymphoma, T-Cell

NCT05744037 2023-02-24

Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

The Affiliated Hospital of Xuzhou Medical University

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, B-Cell

NCT00261612 2006-10-18

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Medical University of Vienna

Phase 2 Unknown
16 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡